Linagliptin

利格列汀

Report date: 2026/03/23 20:03:44
NME

Base Information

Drug NameLinagliptin
Drug Alias Namelinagliptine立那格列汀林格列汀linagliptinum利拉利汀 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)SchizophreniaInflammation +[17] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2011/05/02
Country/TerritoryCzechiaBelgiumBulgaria +[57] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgINTERNATIONAL BIO SERVICES CO LTDEli Lilly And Company +[4] 
Inactive CompaniesGenuine Research Center, EgyptIkfe Cro GmbhBoehringer Ingelheim Pharmaceuticals Inc +[10] 
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)SchizophreniaInflammation +[16] 

Other Information

ATC CodeA10BH05
Related LinksWikipediaDrugBankKEGG